Cargando…

Management of mantle cell lymphoma in the elderly patient

Mantle cell lymphoma is a relatively rare B-cell lymphoma with a specific genetic lesion and a typical immunophenotypic profile. The median age is 65 years. There is no curative treatment, except allogeneic stem cell transplantation for a selected group of patients. For the majority of patients, esp...

Descripción completa

Detalles Bibliográficos
Autores principales: Doorduijn, Jeanette K, Kluin-Nelemans, Hanneke C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783516/
https://www.ncbi.nlm.nih.gov/pubmed/24072968
http://dx.doi.org/10.2147/CIA.S35082
_version_ 1782285683069550592
author Doorduijn, Jeanette K
Kluin-Nelemans, Hanneke C
author_facet Doorduijn, Jeanette K
Kluin-Nelemans, Hanneke C
author_sort Doorduijn, Jeanette K
collection PubMed
description Mantle cell lymphoma is a relatively rare B-cell lymphoma with a specific genetic lesion and a typical immunophenotypic profile. The median age is 65 years. There is no curative treatment, except allogeneic stem cell transplantation for a selected group of patients. For the majority of patients, especially the elderly, the aim of therapy should therefore be a long progression-free survival. Age and comorbidity may hamper the use of the most active treatment regimen, such as high dose cytarabine and autologous stem cell transplantation. Therefore, it is a challenge to select the most appropriate therapy for an elderly patient. Studies specifically designed for elderly patients are rare. A recently performed large randomized study for elderly patients, however, has shown that R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed by maintenance rituximab can result in a long progression-free survival. For patients too frail for R-CHOP chemotherapy, a treatment should be offered that benefits the patient in reducing the symptoms of the disease without causing too many side effects. Progression or relapse will occur in all patients sooner or later. Second-line treatment should again be carefully selected. Several options are mentioned. New drugs are being developed, and new combinations are investigated. Further improvement in the outcome of patients with mantle cell lymphoma is expected. Participation in well-designed clinical trials, also by elderly patients, is important to find the real benefit that can be achieved, and to get information on the tolerability of these treatments in this age group.
format Online
Article
Text
id pubmed-3783516
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-37835162013-09-26 Management of mantle cell lymphoma in the elderly patient Doorduijn, Jeanette K Kluin-Nelemans, Hanneke C Clin Interv Aging Review Mantle cell lymphoma is a relatively rare B-cell lymphoma with a specific genetic lesion and a typical immunophenotypic profile. The median age is 65 years. There is no curative treatment, except allogeneic stem cell transplantation for a selected group of patients. For the majority of patients, especially the elderly, the aim of therapy should therefore be a long progression-free survival. Age and comorbidity may hamper the use of the most active treatment regimen, such as high dose cytarabine and autologous stem cell transplantation. Therefore, it is a challenge to select the most appropriate therapy for an elderly patient. Studies specifically designed for elderly patients are rare. A recently performed large randomized study for elderly patients, however, has shown that R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed by maintenance rituximab can result in a long progression-free survival. For patients too frail for R-CHOP chemotherapy, a treatment should be offered that benefits the patient in reducing the symptoms of the disease without causing too many side effects. Progression or relapse will occur in all patients sooner or later. Second-line treatment should again be carefully selected. Several options are mentioned. New drugs are being developed, and new combinations are investigated. Further improvement in the outcome of patients with mantle cell lymphoma is expected. Participation in well-designed clinical trials, also by elderly patients, is important to find the real benefit that can be achieved, and to get information on the tolerability of these treatments in this age group. Dove Medical Press 2013 2013-09-16 /pmc/articles/PMC3783516/ /pubmed/24072968 http://dx.doi.org/10.2147/CIA.S35082 Text en © 2013 Doorduijn and Kluin-Nelemans. This work is published by Dove Medical Press Ltd, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Ltd, provided the work is properly attributed.
spellingShingle Review
Doorduijn, Jeanette K
Kluin-Nelemans, Hanneke C
Management of mantle cell lymphoma in the elderly patient
title Management of mantle cell lymphoma in the elderly patient
title_full Management of mantle cell lymphoma in the elderly patient
title_fullStr Management of mantle cell lymphoma in the elderly patient
title_full_unstemmed Management of mantle cell lymphoma in the elderly patient
title_short Management of mantle cell lymphoma in the elderly patient
title_sort management of mantle cell lymphoma in the elderly patient
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783516/
https://www.ncbi.nlm.nih.gov/pubmed/24072968
http://dx.doi.org/10.2147/CIA.S35082
work_keys_str_mv AT doorduijnjeanettek managementofmantlecelllymphomaintheelderlypatient
AT kluinnelemanshannekec managementofmantlecelllymphomaintheelderlypatient